# Cabaletta Bio (CABA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/CABA
## Company Profile
- Ticker: CABA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 2.71 USD
- Market cap: 600041649.28 USD
- Last updated: 2026-08-05
## Business Overview
### Autoimmune Cell Therapy Company
Cabaletta Bio develops engineered T-cell therapies intended to produce deep and durable responses in autoimmune disease.
### Rese-cel
Rese-cel is a fully human CD19-directed CAR T-cell therapy being studied across myositis, systemic lupus erythematosus, systemic sclerosis, and pemphigus vulgaris.
### CARTA Platform
The company’s chimeric antigen receptor T-cell strategy for autoimmunity is designed to eliminate disease-causing B cells and reset the immune system after a single treatment.
### Preconditioning-Free Strategy
Cabaletta is evaluating rese-cel without conventional lymphodepleting preconditioning, seeking to simplify treatment and broaden use beyond specialized oncology-style care.
### Scalable Manufacturing
A commercial supply agreement with Cellares provides automated manufacturing capacity intended to support treatment of thousands of patients annually.
## Why The Stock Is Moving

As of Aug 5, 2026, CABA closed down 2.17% at $2.71. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initial preconditioning-free data from the lowest-dose RESET-SLE cohort are expected in the first half of 2026.
- Cabaletta plans to select a second pivotal indication after presentation of complete Phase 1/2 lupus and scleroderma data at the June 2026 EULAR Congress.
- The pivotal RESET-Myositis cohort is intended to support the first rese-cel BLA submission in 2027.

## Drug Assets

- rese-cel

## Recent News
- 2026-06-03 11:00 EST — [Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress](https://biopharmsignal.com/news/CABA/cabaletta-bio-announces-new-rese-cel-data-and-development-updates-across-autoimmune-portfolio-including-encouraging-early-pc-free-lupus-findings-at-eular-2026-congress) — Source: Cabaletta Bio
- 2026-05-14 11:05 EST — [Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CABA/cabaletta-bio-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Cabaletta Bio
- 2026-05-14 11:00 EST — [Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting](https://biopharmsignal.com/news/CABA/cabaletta-bio-presents-preconditioning-free-clinical-data-and-automated-manufacturing-translational-data-for-rese-cel-at-asgct-2026-annual-meeting) — Source: Cabaletta Bio
- 2026-05-04 10:35 EST — [Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering](https://biopharmsignal.com/news/CABA/cabaletta-bio-announces-pricing-of-150-million-underwritten-offering) — Source: Cabaletta Bio
- 2026-04-28 12:00 EST — [Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel](https://biopharmsignal.com/news/CABA/cabaletta-bio-and-cellares-announce-10-year-commercial-supply-agreement-for-rese-cel) — Source: Cabaletta Bio